Ropes & Gray in Silicon Valley:

Driving Innovation in the Bay Area

The outcomes of our matters reshape industries and change lives. That caliber of work gets noticed: we're at the top of the AmLaw A-List and the Financial Times' "FT law firm index," with market-leading capabilities in life sciences, health care, technology, private equity, and asset management. In Silicon Valley, we bring those strengths together to help innovators and investors advance transformative science and technology. This is a firm where exceptional people build extraordinary careers.

Our Silicon Valley office is led by managing partner Megan Baca. Megan's practice reflects the work defining the office: sophisticated AI and digital health transactions; life sciences collaborations, licensing, M&A, and royalty monetization; and complex technology matters. As co-head of the firm's IP Transactions & Licensing group, and Digital Health Initiative, she draws on her computer science background to advise life sciences and technology companies, private equity sponsors, asset managers, and other investors on novel AI, data, and IP issues. Backed by the firm's global platform, our Silicon Valley team offers clients focused local leadership and deep experience across the full lifecycle of transformative technologies and investments.

> "Our associates gain hands-on experience with innovative AI and digital health transactions. In turn, they develop a deep understanding of novel technologies, and the IP issues that come with them, all while benefitting from the support of a close-knit office in the heart of Silicon Valley."
>
> **— Megan Baca, Office Managing Partner**

Silicon Valley By the Numbers

20+ years in Silicon Valley

8 Lawyers in Silicon Valley

Practice Groups Represented: Strategic Transactions (Intellectual Property Transactions)



One Firm. One Team. One Mission.

The matters below are just a few examples of how we break new legal ground.

Alnylam and Inceptive Nucleics Form AI Collaboration

We advised leading RNAi therapeutics company Alnylam Pharmaceuticals in a three-year collaboration with Palo Alto based Inceptive Nucleics to integrate artificial intelligence foundation models with RNA interference (RNAi) therapeutic discovery to catalyze and accelerate progress in nucleic-acid based drug design.

Gilead Sciences, Inc.

We advised Gilead Sciences, Inc. on a definitive agreement to acquire Arcellx for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing.

Profluent, a Berkeley-based AI protein design company

We represented Profluent, on a first-in-kind, open-sourceinspired license of OpenCRISPR-1 granting free access to its new customizable gene editor protein sequences designed with AI to individuals, academic laboratories, drug development companies, and others to use the technology enabling precision editing of the human genome for ethical research and commercial use.

Top Firm, Top Accolades

30 Band 1 Practice Rankings and 36 Band 1 Lawyer Rankings — *Chambers USA*

Top Three for Nine Consecutive Years — *The American Lawyer*

"IP Transactions Firm of the Year" (2023, 2025) — *Managing IP* Americas Awards

California Legal Awards: Finalist in Innovation in Tech/AI (2026) — *Law 360*

Top Three Best Law Firms for Formal Training — *Vault*



ropesgray.com | © 2026 Ropes & Gray LLP. All rights reserved. Prior results do not guarantee a similar outcome.
Communicating with Ropes & Gray LLP or a Ropes & Gray lawyer does not create a client-lawyer relationship.